Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin on Microvascular Dysfunction in HFpEF
NCT06046612Phase 4Unknown
- Sponsor
- Maastricht University Medical Center+
- Start
- Feb 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by Maastricht University Medical Center+. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06046612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046612.